• Arcus Biosciences recently announced a clinical supply agreement with AVEO Oncology to test its investigational HIF-2α inhibitor casdatifan in combination with AVEO’s tivozanib in a new ARC-20 study cohort for patients with advanced clear cell renal cell carcinoma who previously received HIF-2α inhibitor therapy.
• An interesting aspect of this collaboration is that both companies retain development and commercial rights to their respective drugs, potentially influencing how future combination therapies are advanced and monetized in renal cancer.
• We’ll now examine how adding a post–HIF-2α inhibitor renal cancer cohort with tivozanib may influence Arcus Biosciences’ investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Arcus Biosciences Investment Narrative Recap

To own Arcus Biosciences, you need to believe casdatifan and the broader oncology pipeline can convert promising data into approved products before cash burn and competition bite too hard. The new AVEO tivozanib combination cohort adds breadth to casdatifan’s RCC story, but it does not clearly change the key near term catalyst, which remains upcoming casdatifan data readouts, or the central risk around regulatory outcomes and continued operating losses.

The AVEO collaboration fits alongside Arcus’s June 2026 agreement with Bristol Myers Squibb to test casdatifan with pumitamig in the ROSETTA RCC-208 study. Together, these partnerships broaden casdatifan’s combination portfolio in renal cancer just as investors are watching how Arcus manages high clinical spend, partner dependencies, and a revenue base that was only US$17,000,000 in Q1 2026.

Yet while the RCC partnerships expand options for Arcus, investors still need to be aware of the risk that...

Arcus Biosciences’ narrative projects $223.2 million revenue and $42.2 million earnings by 2029. This implies revenues will decline by 1.8% per year and requires an earnings increase of about $411 million from -$369.0 million today.

Uncover how Arcus Biosciences' forecasts yield a $35.75 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some analysts were already assuming roughly 50 percent annual revenue growth and US$150,000,000 in 2029 earnings, so this new RCC combo could either reinforce those optimistic expectations or highlight how uncertain partner dependence and trial outcomes really are for you as a shareholder.

Explore 3 other fair value estimates on Arcus Biosciences - why the stock might be worth just $35.75!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arcus Biosciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Arcus Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcus Biosciences' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.